Arthritis Care & Research · 2015 · 37 citations · 26 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacovigilanceRheumatologyChronic Disease PharmacotherapyDrug Efficacy AssessmentMedication AdherencePharmacoepidemiologyRheumatoid ArthritisAdherence To Chronic Disease TherapiesLogistic RegressionMedication Adherence AnalysisPersistence To TherapyTherapy PersistenceTreatment GapTriple Combination TherapyTriple Therapy Regimens
OBJECTIVE: To estimate adherence and persistence with etanercept plus methotrexate (ETN-MTX) combination therapy and MTX, hydroxychloroquine, and sulfasalazine triple therapy at 1 year following treatment initiation in adults with rheumatoid arthritis (RA). METHODS: This retrospective analysis used data from the Truven Health MarketScan Commercial and Medicare Supplemental databases from January 2009 to July 2013. Adherence was defined as having percentage of days covered >80% for all drugs within each regimen. Persistence was defined as no treatment gap >45 days for any drug and no addition or switching to other disease-modifying antirheumatic drugs. Multiple logistic regression models were employed in the analyses to control for potential confounders. RESULTS: A total of 3,724 ETN-MTX patients and 818 triple therapy patients were eligible. At 1 year, 27.9% who were taking ETN-MTX and 18.2% using triple therapy were adherent to all agents in their regimen (P < 0.0001), and 29.4% who were taking ETN-MTX and 23.2% using triple therapy were persistent (P < 0.001). After adjusting for confounders, ETN-MTX patients had significantly greater odds of being adherent (odds ratio [OR] 1.79, 95% confidence interval [95% CI] 1.47-2.17) and persistent (OR 1.45, 95% CI 1.20-1.72) compared with patients using triple therapy. CONCLUSION: Patients with RA initiating treatment with ETN-MTX combination therapy demonstrated greater adherence and persistence at 1 year than patients initiating triple therapy.
26
Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst et al. · New England Journal of Medicine · 1999 · 2.1K citations · Full text
Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text
Persistence of Use of Lipid-Lowering Medications
Jerry Avorn, Johanne Monette, Anne Sophie Lacour et al. · JAMA · 1998 · 639 citations
Larry W. Moreland, James R. O’Dell, Harold E. Paulus et al. · Arthritis & Rheumatism · 2012 · 388 citations